The tweet was deleted by the author.
But we saved everything 🙂.
Regeneron Pharmaceuticals has announced a significant collaboration with Tessera Therapeutics, aiming to revolutionize genomic medicine.
The partnership will integrate Regeneron's expertise in genetics and genetic medicines with Tessera's innovative Gene Writing™ genome engineering technology.
The collaboration between Regeneron and Tessera builds on a foundation of innovation seen in Regeneron's prior advancements. The company's commitment to advancing heart health was underscored by the release of pivotal Phase 2 data in The Lancet, highlighting progress in cardiovascular research. Meanwhile, groundbreaking developments in hematology were evident when Regeneron unveiled new blood cancer data at ASH25, signaling a broader strategy in genetic and genomic medicine.